Prevalence of dyslipidaemia in statin-treated patients in South Africa: Results of the DYSlipidaemia International Study (DYSIS)

Cardiovascular Journal of Africa

Volumn 24, Issue 8, 2013, Pages 330-338

  Raal, Frederick J ^a   Blom, Dirk J ^b   Naidoo, Shanil ^c   Bramlage, Peter ^d   Brudi, Philippe ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MSD South Africa   (South Africa)

^d Institut fur Pharmakologie und Praventive Medizin   (Germany)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular disease (CVD); Dyslipidaemia; Lipid abnormalities; Low density lipoprotein cholesterol (LDL C); Statins

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DRUG SCREENING; DYSLIPIDEMIA; FEMALE; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; SOUTH AFRICA; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84889246065     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2013-071     Document Type: Article

References (46)

1. Cardiovascular diseases (CVDs) Fact sheet no. 317: World Health Organization; September 2012. Available from: http://www.who.int/mediacentre/ factsheets/fs317/en/index.html.
2. Mortality and causes of death in South Africa, 2009: Findings from death notification: Statistics South Africa; November 2011. Available from: http://www.statssa.gov.za/default.asp.
3. Mortality and causes of death in South Africa, 2008: Findings from death notification: Statistics South Africa; November 2010. Available from: http://www.statssa.gov.za/default.asp.
4. Mortality and causes of death in South Africa, 1997 to 2003: Findings from death notification.: Statistics South Africa; November 2010. Available from: http://www.statssa.gov.za/default.asp.
5. Maredza M HK, Tollman SM. A hidden menace: Cardiovascular disease in South Africa and the costs of inadequate policy response. SA Heart J 2011; 8(1): 48-57.
6. Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. Lancet 2009; 374(9693): 934-947. PubMed PMID: 19709736.
7. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Current problems in cardiology. 2010; 35(2): 72-115. PubMed PMID: 20109979. Pubmed Central PMCID: 2864143. Epub 2010/01/30. eng.
8. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 2010; 31(6): 642-648. PubMed PMID: 20176800. Epub 2010/02/24. eng.
9. South Africa: World Health Organization; 2011. Available from: http://www.who.int/nmh/countries/zaf-en.pdf.
10. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Prac 2010; 87(1): 4-14. PubMed PMID: 19896746. Epub 2009/11/10. eng.
11. Bradshaw D, Norman R, Pieterse D, Levitt NS. Estimating the burden of disease attributable to diabetes in South Africa in 2000. South Afr Med J 2007; 97(8 Pt 2): 700-706. PubMed PMID: 17952227. Epub 2007/10/24. eng.
12. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011 (1): CD004816. PubMed PMID: 21249663. Epub 2011/01/21. eng.
13. Mamdoo FRF. Statins: targeting cardiovascular disease. South Afr Heart J 2008; 5(2): 66-69.
14. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharmaceut Design 2009; 15(5): 467-478.PubMed PMID: 19199975. Pubmed Central PMCID: 2896785. Epub 2009/02/10. eng.
15. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-1278. PubMed PMID: 16214597. Epub 2005/10/11. eng.
16. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368(9539): 919-928. PubMed PMID: 16962881. Epub 2006/09/12. eng.
17. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117-125. PubMed PMID: 18191683. Epub 2008/01/15. eng.
18. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Int Med 2004; 164(13): 1427-1436. PubMed PMID: 15249352. Epub 2004/07/14. eng.
19. Cholesterol treatment trialists, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681. PubMed PMID: 21067804. Pubmed Central PMCID: 2988224.
20. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380(9841): 565-571. PubMed PMID: 22883507. Epub 2012/08/14. eng.
21. Klug E. South African dyslipidaemia guideline consensus statement. South Afr Med J 2012; 102(3 Pt 2): 178-187. PubMed PMID: 22380916. Epub 2012/03/03. eng.
22. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012; 223(1): 1-68. PubMed PMID: 22698795. Epub 2012/06/16. eng.
23. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-239. PubMed PMID: 15249516. Epub 2004/07/14. eng.
24. Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prevent Cardiol 2012; 19(2): 221-30. PubMed PMID: 21450578. Epub 2011/04/01. eng.
25. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic Med 2011; 28(11): 1343-1351. PubMed PMID: 21679231. Epub 2011/06/18. eng.
26. Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M, et al. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr 2011; 22(5): 234-240. PubMed PMID: 21922121.
27. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80(1): 106-107. PubMed PMID: 9205036. Epub 1997/07/01. eng.
28. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias, the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(1): 3-46. PubMed PMID: 21882396. Epub 2011/09/02. eng.
29. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathways Cardiol 2005; 4(4): 198-203. PubMed PMID: 18340209.
30. Al Sifri SN, Almahmeed W, Azar S, Okkeh O, Bramlage P, Jünger C, et al. Results of the Dyslipidemia International Study (DYSIS)-Middle East: a clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. In press 2013
31. Hempler NF, Diderichsen F, Larsen FB, Ladelund S, Jorgensen T. Do immigrants from Turkey, Pakistan and Yugoslavia receive adequate medical treatment with beta-blockers and statins after acute myocardial infarction compared with Danish-born residents? A register-based follow-up study. Eur J Clin Pharmac 2010; 66(7): 735-742. PubMed PMID: 20393695.
32. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010; 48(3): 196-202. PubMed PMID: 19890219.
33. Traylor AH, Schmittdiel JA, Uratsu CS, Mangione CM, Subramanian U. Adherence to cardiovascular disease medications: does patient provider race/ethnicity and language concordance matter? J Gen Int Med 2010; 25(11): 1172-1177. PubMed PMID: 20571929. Pubmed Central PMCID: 2947630.
34. Sliwa K, Lyons JG, Carrington MJ, Lecour S, Marais AD, Raal FJ, et al. Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease. Cardiovasc J Afr 2012; 23(7): 389-395. PubMed PMID: 22914997.
35. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008; 197(2): 710-717. PubMed PMID: 17765905. Epub 2007/09/04. eng.
36. Sudano I, Hess L, Noll G, Arnet D. Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients. Swiss Med Weekly 2011; 141: w13200. PubMed PMID: 21574067. Epub 2011/05/17. eng.
37. Eber B, Lautsch D, Fauer C, Drexel H, Pfeiffer KP, Traindl O, et al. Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. Curr Med Res Opin 2012; 28(9): 1447-1454. PubMed PMID: 22856551. Epub 2012/08/04. eng.
38. Bandgar TR, Faruqui AA. Managing dyslipidaemia: evolving role of combination therapy. J Indian Med Assoc 2011;109(8): 549-552. PubMed PMID: 22315861. Epub 2012/02/10. eng.
39. Ito MK. Dyslipidemia: management using optimal lipid-lowering therapy. Ann Pharmacother 2012; 46(10): 1368-1381. PubMed PMID: 23032652. Epub 2012/10/04. eng.
40. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010 (3): CD004371. PubMed PMID: 20238331.
41. Dragomir A, Cote R, White M, Lalonde L, Blais L, Berard A, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health 2010; 13(1): 87-94. PubMed PMID: 19695008.
42. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155(4): 772-779. PubMed PMID: 18371492.
43. McGinnis BD, Olson KL, Delate TM, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Managed Care 2009; 15(10): 689-695. PubMed PMID: 19845421.
44. Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008; 66(1): 110-116. PubMed PMID: 18492127. Pubmed Central PMCID: 2485263.
45. Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Commun Health 2010; 64(2): 109-113. PubMed PMID: 20056964.
46. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract 2012; 66(3): 270-280. PubMed PMID: 22340447.